4Front Ventures
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
4Front Ventures lands at 38 on the CIN composite, a Neutral outcome with conviction of 3/5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Regulatory carries this profile, printing 49 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.
The observable inputs tell a straightforward story: reported revenue growth of -25.5 percent year over year, an operating margin of -38.4 percent, a jurisdictional posture reading of 50. Every figure is auditable in the accompanying pillar table. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets 4Front Ventures be lined up against the US operator peer set on identical inputs, with refresh cadence tied directly to primary-source ingest.
Filing cadence and jurisdictional posture remain the primary drivers, with regulatory contributing 49. A sustained lift in filing frequency across the trailing 90 days combined with zero enforcement events would tighten the Neutral conclusion.
- CEO
- Leo Go***r
- SEC CIK
- 0001783875
- Website
- Company website
- Market cap
- $0.0M
- Enterprise value
- $212.9M
- Price to book
- 3.31
- EV / EBITDA
- -258.86
- Revenue (TTM)
- $75.6M
- Gross profit (TTM)
- $26.9M
- EBITDA
- $-17.0M
- Operating margin
- -38.4%
- Profit margin
- -48.1%
- Rev growth YoY
- -25.5%
- Return on equity
- -182.7%
- Return on assets
- -5.1%
- EPS (TTM)
- $-0.11
- Wall St. target price
- $2.37
- Shares outstanding
- 913.9M
- Insider ownership
- 51.1%
- Institutional ownership
- 6.7%
- Beta
- 0.17
- Full-time employees
- 374
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for 4Front Ventures (FFNTF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for 4Front Ventures (FFNTF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for FFNTF are maintained by Cannabis Investor News and refreshed throughout the trading day.